about
Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cellsPancreatic cancer: pathobiology, treatment options, and drug delivery.DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinomaHypoxia triggers hedgehog-mediated tumor-stromal interactions in pancreatic cancer.The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.Role of polyamines in determining the cellular response to chemotherapeutic agents: modulation of protein kinase CK2 expression and activity.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drugs in the treatment of pancreatic cancer.
@en
Emerging drugs in the treatment of pancreatic cancer.
@nl
type
label
Emerging drugs in the treatment of pancreatic cancer.
@en
Emerging drugs in the treatment of pancreatic cancer.
@nl
prefLabel
Emerging drugs in the treatment of pancreatic cancer.
@en
Emerging drugs in the treatment of pancreatic cancer.
@nl
P2093
P2860
P1476
Emerging drugs in the treatment of pancreatic cancer.
@en
P2093
Devalingam Mahalingam
Francis J Giles
Jennifer Carew
Kevin R Kelly
Ronan T Swords
Steffan T Nawrocki
P2860
P304
P356
10.1517/14728210902972502
P407
P577
2009-06-01T00:00:00Z